In animal study, they found that interleukin-33 (IL33) activates tumor ILC2s and CD8+ T cells to limit pancreas-specific tumor growth in orthotopic pancreatic tumors but not heterotopic skin tumors [62]. Here, IL33 is linked to neoplasm.